- ASSISTANT PROFESSOR Medicine, Endocrinology, Diabetes and Bone Disease
Chen H, Gu X, Liu Y, Wang J, Wirt S, Bottino R, Schorle H, Sage J, Kim SK. PDGF signaling controls age-dependent proliferation in pancreatic Beta-cells. Nature 2011; 478(7369): 349-55.
Chen H, Gu X, Su I, Bottino R, Contreras JL, Tarakhovsky A, Kim SS. Polycomb protein Ezh2 regulates pancreatic Beta-cell Ink4a/Arf expression and regeneration in diabetes mellitus.. Genes & Development, 2009; 23(8): 975-85.
Karnik SK, Chen H, McLean GW, Heit JJ, Gu X, Zhang AY, Fontaine M, Yen MH, Kim SK. Menin controls growth of pancreatic beta cells in pregnant mice and promotes gestational diabetes mellitus. Science 2007; 318(5851): 806-9.
Rulifson IC, Karnik SK, Heiser PW, Berge DT, Chen H, Gu X, Taketo MM, Nusse R, Herbrok M, Kim SK. Wnt signaling regulates pancreatic Beta-cell proliferation. Proc Natl Acad Sci, USA 2007; 104(15): 6247-52.
Li X, Chen H, Epstein PN. Metallothionein and catalase sensitize to diabetes in Nonobese Diabetic Mice: reactive oxygen species may have a protective role in pancreatic -cells. Diabetes 2006; 55(6): 1592-1604.
Chen H, Li X, Epstein PN. MnSOD and catalase transgenes demonstrate that protection of islets from oxidative stress does not alter cytokine toxicity. Diabetes 2005; 54(5): 1437-46.
Li X, Chen H, Epstein PN. Metallothionein protects islets from hypoxia and extends islet graft survival by scavenging most kinds of reactive oxygen species. J. Biol. Chem 2004; 279(1): 765-771.
Chen H, Carlson EC, Pellet L, Moritz JT, Epstein PN. Overexpression of metallothionein in pancreatic beta cells reduces streptozotocin induced DNA damage and diabetes. . Diabetes 2001; 50(9): 2040-2046.
Li X, Zhu C, Chen H, Zhu Y, Wu G, Xu S. Effects of fenfluramine combined with electroacupuncture on monoamine release in periaqueductual gray of rat brain. Acta Pharmacol Sin 1999; 20(7): 597-600.
Chen H, Hu Y, Xia X. Variation of glycosidases during the development of rat hepatoma induced by diethylnitrosamine. Chinese Biochemical Journal 1993; 37(6): 80-82.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Chen did not report having any of the following types of financial relationships with industry during 2014 and/or 2015: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.
Atran Berg Laboratory Building Floor 5th Floor Room Room AB5-17
1428 Madison Avenue
New York, NY 10029